Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Abbott India Ltd. stands out in the Pharmaceuticals & Drugs sector with remarkable profitability metrics, although its growth indicators are currently stagnant. It showcases the highest ROE and ROCE among peers, making it a strong candidate despite its high valuation. Companies like Cipla and Dr. Reddy's present robust growth and valuation metrics, while others like Sun Pharma are showing signs of being overvalued due to high P/E ratios.
Highest ROE (37.45%) and ROCE (49.12%) indicating strong profitability.
Strong revenue growth (YoY: 13.28%) with attractive valuation (PE: 23.73).
Solid revenue growth (16.54% YoY) and low PE (15.50) making it highly attractive.